Endurant Capital Management LP Gritstone Bio, Inc. Transaction History

Endurant Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $548,947 - $963,880	257,722 Added 91.09%	540,657 $1.5 Million
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $613,968 - $1.11 Million	282,935 New	282,935 $976,000
Q3 2019 Nov 14, 2019	SELL	$8.45 - $12.28 $1.21 Million - $1.77 Million	-143,752 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.2 - $15.7 $1.13 Million - $1.92 Million	122,495 Added 576.26%	143,752 $1.6 Million
Q1 2019 May 15, 2019	BUY	$9.97 - $18.96 $211,932 - $403,032	21,257 New	21,257 $283,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Endurant Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Endurant Capital Management LP with notifications on news.